Kedrion Biopharma announces that it has commenced patient enrollment in its new CARES10 (Clinical Assessment of phaRmacokinetics, Efficacy, Safety of a 10% Ig) clinical study.
CARES10 is a US/CANADA-based open label multicenter phase 3 clinical study to assess efficacy, safety and pharmacokinetics of a 10% intravenous Immunoglobulin (KIg10) in the treatment of adult patients with Primary Immunodeficiency Diseases (PID).
The first patient was screened on April 30th, 2019 and has been receiving treatment since May 10th. In line with the plan, seventeen patients have been enrolled so far. Enrollments will continue until January 2020 with the goal of reaching a total of around 50 patients. The study is scheduled to be completed by Q2 2021.